Intercure Continuing Its Medical Cannabis Consolidation Strategy, Announces Strategic Acquisition Of Cannomed Pharmacy Chain
Intercure Continuing Its Medical Cannabis Consolidation Strategy, Announces Strategic Acquisition Of Cannomed Pharmacy Chain
09/02/21, 1:41 PM
Industry
agriculture and farming
food and beverage
consumer goods
other
health care
community and lifestyle
InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) today announced that it has signed an agreement in which InterCure will purchase strategic assets from Cannomed (TASE: CNMD), an Israel-based company and owner of a pharmacy chain specializing in dispensing medical cannabis.
Company Info
Company info
InterCure (dba Canndoc)
InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to maintain its position as Israel’s leading cannabis company as well as to drive further growth through global expansion.
For more information, visit: http://www.intercure.co